US EditionTrump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149 via TrumpRx: Report
- This past week the Trump administration negotiated with Eli Lilly and Novo Nordisk to cut Zepbound and Wegovy prices to as low as $149 a month, people familiar with the talks said.
- President Donald Trump revived the drug‑pricing initiative via the May executive order, while list prices for Zepbound and Wegovy remain above $1,000, prompting lower‑cost cash options and retailer deals.
- Companies would agree to sell directly to consumers at below-list prices, but it remains unclear if private insurers or Medicare would cover reduced cash prices or which Medicare patients qualify.
- The deal could be announced as early as Thursday, with final pricing expected by Nov. 1 and new prices unveiled by Nov. 30, marking a key outcome of President Donald Trump’s drug‑pricing initiative.
- The White House spokesperson Kush Desai cautioned that discussions about unannounced deals should be regarded as speculation, as reported by Endpoint News.
97 Articles
97 Articles
Trump announces deal to lower price of Ozempic, Mounjaro
President Donald Trump announced Thursday morning that Novo Nordisk and Eli Lilly have agreed to lower the price of two popular GLP-1 medications for weight loss. Lilly’s Zepbound will now cost $346 per month, down from $1,080, while Novo’s Wegovy will now cost $250, down from $1,350, Trump said. Both companies also agreed to sell oral GLP-1 medications, which are currently under development, for no more than $149 per month. “The United States …
TrumpRx: Trump Scores Significantly Lower Prices For Popular Weight Loss Drugs
President Donald Trump announced on Thursday that he’s reached deals with major pharmaceutical companies to lower the costs of popular weight loss drugs known as GLP-1s.Pharma companies Eli Lilly, which makes Zepbound, and Novo Nordisk, which makes Wegovy and Ozempic, have agreed to lower prices of their drugs to the tune of hundreds of dollars, Trump said. Notably, Ozempic is primarily a type 2 diabetes medication, but is often prescribed off-l…
Pittsburgh Post-Gazette
The Washington PostWhite House nears deal to lower obesity drug prices for Medicare coverage
The White House is expected to announce a deal this week with Eli Lilly and Novo Nordisk that would lower the price of their popular obesity drugs to $149...
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
